Bamco Inc. NY Invests $321,000 in Janux Therapeutics, Inc. (NASDAQ:JANX)

Bamco Inc. NY purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 6,000 shares of the company’s stock, valued at approximately $321,000.

Several other hedge funds have also added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the period. Avanza Fonder AB acquired a new position in Janux Therapeutics in the fourth quarter valued at approximately $139,000. Meeder Asset Management Inc. acquired a new position in Janux Therapeutics in the fourth quarter valued at approximately $159,000. Tower Research Capital LLC TRC boosted its stake in Janux Therapeutics by 878.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after acquiring an additional 3,436 shares during the last quarter. Finally, Chicago Capital LLC acquired a new stake in Janux Therapeutics during the 4th quarter worth $230,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $29.79 on Tuesday. The stock has a market capitalization of $1.76 billion, a price-to-earnings ratio of -25.46 and a beta of 3.24. Janux Therapeutics, Inc. has a fifty-two week low of $22.52 and a fifty-two week high of $71.71. The business has a 50-day moving average of $29.74 and a 200-day moving average of $42.33.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at approximately $2,640,768.85. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ra Capital Management, L.P. bought 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The stock was acquired at an average cost of $30.64 per share, with a total value of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares of the company’s stock, valued at $295,951,392.32. This trade represents a 3.67 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 10,001 shares of company stock worth $313,964. Insiders own 29.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on JANX shares. Scotiabank decreased their price objective on Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research note on Friday, February 28th. Wedbush reaffirmed an “outperform” rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $70.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics presently has an average rating of “Buy” and a consensus price target of $95.25.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.